Nesiritide (BNP) in the management of postoperative cardiac patients.
Recombinant human B-type natriuretic peptide (BNP) is a promising new agent in the management of heart failure. The pharmacologic properties of BNP make it desirable to use in a subset of patients after cardiac surgical operations. Among these therapeutic potentials is the effect on markedly reducing pulmonary vascular resistance and central venous pressure with mild systemic vasodilatation. In addition, BNP directly effects the kidneys to promote natriuresis. We believe this agent to be useful in the treatment of the postcardiac surgery patients with left ventricular dysfunction and mild to moderate renal insufficiency. This report summarizes our experience in 2 patients.
Moazami
Nader
N
Division of Cardiothoracic Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, Missouri 63110-1013, USA. moazamin@msnotes.wustl.edu
Damiano
Ralph J
RJ
Bailey
Marci S
MS
Hess
Rachel L
RL
Lawton
Jennifer S
JS
Moon
Marc R
MR
Pasque
Michael K
MK
D000368:Aged; D000369:Aged, 80 and over; D002315:Cardiopulmonary Bypass; D002496:Central Venous Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009203:Myocardial Infarction / Q000601:surgery*; D009318:Natriuresis / Q000187:drug effects; D045283:Natriuretic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D020097:Natriuretic Peptide, Brain; D011183:Postoperative Complications / Q000188:drug therapy*; D011651:Pulmonary Artery / Q000187:drug effects; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy*
D045283:Natriuretic Agents; D020097:Natriuretic Peptide, Brain